Sage Therapeutics
SAGESage Therapeutics, Inc. (NASDAQ: SAGE) is a biopharmaceutical company based in the United States. Its primary business focus is the development and commercialization of novel medicines designed to treat disorders of the brain. The company's research and development efforts are concentrated on specific therapeutic areas within neuroscience, including major depressive disorder, postpartum depression, and various neurological and neuropsychiatric conditions. The company's first approved product, ZULRESSO® (brexanolone) injection, is indicated for the treatment of postpartum depression in adults. Sage also markets ZURZUVAE™ (zuranolone), an oral neuroactive steroid, which is approved for the treatment of postpartum depression in adults and is being evaluated for other mood disorders. Beyond these commercialized assets, Sage Therapeutics maintains a clinical-stage pipeline investigating compounds for conditions such as cognitive impairment associated with Huntington’s disease and essential tremor. As a publicly traded entity, Sage Therapeutics operates within the competitive biotechnology and neuroscience sectors. The company’s strategy involves advancing its pipeline through clinical trials and pursuing regulatory pathways for its candidate therapies. Its financial performance and operational milestones are documented in its filings with the U.S. Securities and Exchange Commission.
About
Sage Therapeutics, Inc. (NASDAQ: SAGE) is a biopharmaceutical company based in the United States. Its primary business focus is the development and commercialization of novel medicines designed to treat disorders of the brain. The company's research and development efforts are concentrated on specific therapeutic areas within neuroscience, including major depressive disorder, postpartum depression, and various neurological and neuropsychiatric conditions. The company's first approved product, ZULRESSO® (brexanolone) injection, is indicated for the treatment of postpartum depression in adults. Sage also markets ZURZUVAE™ (zuranolone), an oral neuroactive steroid, which is approved for the treatment of postpartum depression in adults and is being evaluated for other mood disorders. Beyond these commercialized assets, Sage Therapeutics maintains a clinical-stage pipeline investigating compounds for conditions such as cognitive impairment associated with Huntington’s disease and essential tremor. As a publicly traded entity, Sage Therapeutics operates within the competitive biotechnology and neuroscience sectors. The company’s strategy involves advancing its pipeline through clinical trials and pursuing regulatory pathways for its candidate therapies. Its financial performance and operational milestones are documented in its filings with the U.S. Securities and Exchange Commission.